Status: Recruiting
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Participants needed: 739
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: SWOG Cancer Research NetworkUpdated: Apr 2, 2026Locations: 723
Eligibility criteria
STEP 1 REGISTRATION [+28]